Loading...
•
Apr 30, 2021
Medtronic Q4 2021 Earnings Report
Medtronic's Q4 2021 financial results reflected a strong recovery with revenue increasing 37% as reported and 32% organically.
Key Takeaways
Medtronic reported a strong end to fiscal year 2021, with fourth quarter revenue of $8.188 billion, a 37% increase as reported and 32% organically. GAAP diluted EPS was $1.00, and non-GAAP diluted EPS was $1.50. The company announced a 9% dividend increase and issued FY22 guidance.
Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
Q4 GAAP Diluted EPS of $1.00; Q4 Non-GAAP Diluted EPS of $1.50
Quarterly Dividend Increased to $0.63, Annual $2.52 from Prior $2.32; 44th Consecutive Year of Dividend Increases
Company Issues FY22 Guidance
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company expects revenue growth in its fiscal year 2022 to approximate 9 percent on an organic basis. In fiscal year 2022, the company expects diluted non-GAAP EPS in the range of $5.60 to $5.75, including an estimated 10 to 15 cent positive impact from foreign currency based on current exchange rates.
Positive Outlook
- Strong organic revenue growth driven by new product launches
- End market recovery from the impact of the pandemic
- Investing at the front end of major product launches, including surgical robotics and renal denervation, to fully realize their potential
- Planning for the largest increase in R&D spend in company’s history
- Capitalizing on a long list of opportunities
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...